Herbert Smith Freehills advises Lupin Healthcare on acquisition of Renascience Pharma

Leading international law firm Herbert Smith Freehills has advised Lupin Healthcare (UK) Limited (Lupin), the UK subsidiary of Lupin Limited, on the acquisition of Renascience Pharma Limited (Renascience), a reputable UK-based licensee and sole supplier of four niche branded generics products.

Lupin is a global, multinational pharmaceutical company headquartered in Mumbai, India. Lupin develops and commercialises a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets including the USA, India, South Africa and across Asia Pacific, Latin America, Middle East regions and Europe.

Lupin's plans will focus on growing the portfolio of Renascience's brands in alignment with NHS priorities.

The Herbert Smith Freehills team was led by Corporate partner Alan Montgomery and senior associate Faria Ali, supported by associates Arina Abgaryan and Toby Goodman. The wider team included Christine Young, Hannah White, Erin McKirdy, Andrew Wells, Joshua Sanchez-Lawson, Casey Dalton, James Hollis, Frank Thompson, Hayley Brady, James Balfour, Georgie Green, Peter Dalton, Sabesh Asokan, Miriam Everett, William Turnbull, Haleema Ishaq, Duc Tran, Chiazam Mozie, Michael Aherne and Jia Liu. They worked closely with Thomas Ghignone, Senior Vice President, Legal, at Lupin.

Partner Alan Montgomery said: "We are immensely proud to have advised long-standing client Lupin on yet another successful transaction and one which enhances Lupin's branded medicine portfolio, catering to unmet medical needs."